DiaGenic Terminates Contract with Investment Firm Terra Markets | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – DiaGenic today announced it has terminated its market-making contract with investment firm Terra Markets, effective March 1.

DiaGenic, based in Oslo, Norway, had an agreement with Terra to ensure sufficient trading of its shares, which lists on the Oslo Stock Exchange. But with trading of the company's stock "very high," the molecular diagnostic developer decided that it no longer needed Terra's services, DiaGenic CEO Erik Christensen said in an e-mail.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.